Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.62 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.62 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2845539 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL30897545 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL29359402 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL133106 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL14612812 | 0.90 | CYP1A2 (0.82) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL7265346 | 0.89 | CYP1A2 (0.80) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL11369967 | 0.89 | CYP1A2 (0.79) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL11004406 | 0.89 | CYP1A2 (0.79) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL7272013 | 0.88 | MAPT (0.79) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL28830138 | 0.87 | MAPT (0.78) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594257-B2 | Means and methods for improving anti-tumoral efficacy of transmembrane channel protein blockers | ARDAN PHARMA S.A.S. (AR) | 2026-04-07 | — | — | US | claimed |
| US-20240148687-A1 | MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERS | ARDAN PHARMA S.A.S. (AR) | 2024-05-09 | — | — | US | claimed |
| US-11246858-B2 | Immunoresponsive methods of treating tumors | INSTITUT PASTEUR DE MONTEVIDEO (UY) | 2022-02-15 | — | — | US | claimed |
| US-12624342-B2 | Methods for reprogramming cells and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2026-05-12 | — | — | US | disclosed |
| US-12594257-B2 | Means and methods for improving anti-tumoral efficacy of transmembrane channel protein blockers | ARDAN PHARMA S.A.S. (AR) | 2026-04-07 | — | — | US | disclosed |
| US-12263143-B2 | Ionic channel modulation as a method for treating tumors through inflammasome activation | INSTITUT PASTEUR DE MONTEVIDEO (UY) | 2025-04-01 | — | — | US | disclosed |
| WO-2024163615-A1 | BRAIN-DERIVED NEUROTROPHIC FACTOR-NANO LUCIFERASE TRANSGENIC RODENTS AND METHODS OF USE THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-08 | — | — | WO | disclosed |
| US-12024722-B2 | Methods for reprogramming cells and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2024-07-02 | — | — | US | disclosed |
| US-20240148687-A1 | MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERS | ARDAN PHARMA S.A.S. (AR) | 2024-05-09 | — | — | US | disclosed |
| EP-4346775-A1 | MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERS | Ardan Pharma S.a.s. (AR) | 2024-04-10 | — | — | EP | disclosed |
| US-11795439-B2 | Methods for reprogramming cells and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2023-10-24 | — | — | US | disclosed |
| US-8268795-B2 | Emergence of a R-type CA2+ channel (CAV 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120053120-A1 | TREATMENT OF SUBARACHNOID HEMORRHAGE WITH APO E ANALOGS | COGNOSCI, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-8034762-B2 | Treatment of subarachnoid hemorrhage with Apo E analogs | COGNOSCI, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110086903-A1 | EMERGENCE OF A R-TYPE CA2+ CHANNEL (CAV 2.3) CONTRIBUTES TO CEREBRAL ARTERY CONSTRICTION FOLLOWING SUBARACHNOID HEMORRHAGE | NATIONAL INSTITUTES OF HEALTH | 2011-04-14 | — | — | US | disclosed |
| US-7829527-B2 | Emergence of a R-type Ca2+ channel (Cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100028912-A1 | IMAGING USING RADIOACTIVE MONOCATIONS IN COMBINATION WITH A RECEPTOR BINDING LIGAND THAT STIMULATES THE INFLUX OF CATIONS | BRACCO IMAGING S.P.A. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20090131315-A1 | Treatment of Subarachnoid Hemorrhage With APO E Analogs | CORNERSTONE BIOSCIENCES, INC. | 2009-05-21 | — | — | US | disclosed |
| WO-2008082545-A2 | IMAGING USING RADIOACTIVE MONOCATIONS IN COMBINATION WITH A RECEPTOR BINDING LIGAND THAT STIMULATES THE INFLUX OF CATIONS | BRACCO IMAGING S.P.A. (IT) | 2008-07-10 | — | — | WO | disclosed |
| US-20060229269-A1 | Emergence of a R-type Ca²+ channel (Cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624342-B2 | Methods for reprogramming cells and uses thereof | DNMT3B, TRDMT1, MECP2 | CYP1A2 4669/4885ADORA3 4538/4885MAPT 4435/4885 |
| US-12594257-B2 | Means and methods for improving anti-tumoral efficacy of transmembrane channel protein blockers | TMEM94, TMEM126A, TMEM41B | CYP1A2 3844/4885ADORA3 4451/4885MAPT 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.